Opportunity Information: Apply for RFA MH 19 412
The Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum funding opportunity (RFA-MH-19-412) is a National Institutes of Health (NIH) discretionary grant program using the R01 mechanism, with clinical trials allowed but not required ("Clinical Trial Optional"). Its overall purpose is to strengthen HIV prevention by tackling intersectional stigma, meaning the overlapping and reinforcing effects of multiple stigmatized identities (for example, stigma related to race/ethnicity, sexual orientation, gender identity, substance use, poverty, immigration status, involvement with the criminal legal system, or sex work). The FOA focuses on how these combined stigmas can block people from getting HIV tested and from successfully linking to and staying engaged in ongoing HIV prevention services.
The opportunity supports two main types of research. First, it encourages studies that improve how intersectional stigma is measured and understood, including creating or refining tools and metrics that capture real-world experiences of layered stigma across settings (such as healthcare, community environments, and social networks). In addition to measurement development, this research track also emphasizes identifying mechanisms and pathways, essentially mapping how intersectional stigma leads to reduced HIV testing, delayed engagement with prevention, poor linkage to services, or drop-off along the HIV prevention continuum. Projects under this aim would typically try to clarify where stigma shows up (interpersonal interactions, institutional policies, clinic practices, internalized stigma), how it affects behavior and decision-making, and what factors mediate or moderate its impact.
Second, the FOA supports the development and testing of interventions specifically designed to reduce intersectional stigma and improve HIV prevention outcomes. This includes designing approaches that can be implemented in clinical, community, or hybrid settings and then evaluating whether these interventions increase uptake of HIV testing and strengthen linkage to prevention services, including ongoing prevention engagement among key populations at substantial risk for HIV infection. Because the announcement is "clinical trial optional," applicants can propose either observational/mechanistic studies or intervention studies that may rise to the level of a clinical trial, depending on the design.
From an administrative standpoint, the program is offered as a grant, with an award ceiling listed as $499,999. The original closing date in the source information is 2019-01-23, and the FOA record shows a creation date of 2018-11-23. The CFDA numbers associated with this opportunity are 93.242 and 93.307, indicating the federal assistance listings tied to NIH programs relevant to the topic area.
Eligibility is broad and includes many types of applicants across government, academia, nonprofit, and private sectors. Eligible applicants explicitly include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible applicant groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). In practical terms, this broad eligibility signals an interest in supporting research that is scientifically rigorous while also being grounded in the communities most affected, including work led by or conducted in partnership with community organizations and institutions serving populations disproportionately impacted by HIV and stigma.
Taken together, PRISM is aimed at producing both better science (more accurate measurement and clearer causal explanations of how intersectional stigma disrupts prevention) and actionable solutions (interventions that reduce stigma and measurably improve HIV testing and prevention linkage). The emphasis on key populations at substantial risk for HIV infection and on improving the prevention continuum indicates that applicants are expected to connect stigma reduction not just to attitudes or experiences, but to concrete prevention outcomes such as testing uptake and successful connection to ongoing prevention services.Apply for RFA MH 19 412
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.307.
- This funding opportunity was created on 2018-11-23.
- Applicants must submit their applications by 2019-01-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $499,999.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
PRISM (RFA-MH-19-412) FAQ
What is the PRISM funding opportunity?
PRISM stands for Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum. It is an NIH discretionary grant funding opportunity (RFA-MH-19-412) that supports research intended to strengthen HIV prevention by addressing intersectional stigma and its effects on HIV testing and engagement in prevention services.
Which NIH grant mechanism is used for PRISM?
This opportunity uses the R01 research project grant mechanism.
Are clinical trials required under this FOA?
No. The FOA is "Clinical Trial Optional," meaning clinical trials are allowed but not required. Applications can propose observational/mechanistic research or intervention research, depending on the scientific aims and design.
What is the overall purpose of PRISM?
The purpose is to improve the HIV prevention continuum by tackling intersectional stigma, especially where overlapping stigmas reduce HIV testing, delay linkage to prevention services, or lead to drop-off in ongoing prevention engagement.
What does "intersectional stigma" mean in this FOA?
Intersectional stigma refers to overlapping and reinforcing effects of multiple stigmatized identities. The FOA describes examples such as stigma related to race/ethnicity, sexual orientation, gender identity, substance use, poverty, immigration status, involvement with the criminal legal system, or sex work. The focus is on how these combined stigmas can create barriers to HIV testing and prevention services.
What parts of the HIV prevention continuum does PRISM focus on?
The FOA highlights barriers to (1) getting HIV tested, (2) successfully linking to prevention services, and (3) staying engaged in ongoing HIV prevention services.
What types of research does PRISM support?
The FOA supports two main research tracks: (1) studies to improve measurement and understanding of intersectional stigma and identify mechanisms/pathways linking stigma to HIV prevention outcomes, and (2) development and testing of interventions designed to reduce intersectional stigma and improve HIV prevention outcomes.
What is included in the measurement and understanding research track?
This track emphasizes improving how intersectional stigma is measured and understood. It includes creating or refining tools and metrics that capture real-world experiences of layered stigma across settings (including healthcare, community environments, and social networks). It also emphasizes identifying mechanisms and pathways that explain how intersectional stigma leads to reduced HIV testing, delayed engagement with prevention, poor linkage, or drop-off along the prevention continuum.
What kinds of settings can measurement tools or studies focus on?
The FOA explicitly mentions healthcare settings, community environments, and social networks as examples of settings where layered stigma can be experienced and measured.
What does it mean to identify "mechanisms and pathways" in this FOA?
In this context, it means mapping how intersectional stigma translates into HIV prevention barriers. The FOA points to clarifying where stigma shows up (for example, interpersonal interactions, institutional policies, clinic practices, or internalized stigma), how it affects behavior and decision-making, and what factors mediate or moderate its impact on prevention outcomes.
What is included in the intervention research track?
This track supports developing and testing interventions specifically designed to reduce intersectional stigma and improve HIV prevention outcomes. Interventions may be designed for clinical, community, or hybrid settings and evaluated for whether they increase HIV testing uptake and strengthen linkage to prevention services, including ongoing prevention engagement.
Where can PRISM interventions be implemented?
The FOA indicates interventions can be implemented in clinical settings, community settings, or hybrid models that involve both.
What outcomes should PRISM interventions aim to improve?
The FOA emphasizes concrete HIV prevention outcomes, including increased uptake of HIV testing, improved linkage to prevention services, and stronger ongoing engagement in prevention services among key populations at substantial risk for HIV infection.
Does PRISM only fund intervention studies?
No. PRISM supports both measurement/mechanistic studies and intervention development/testing. Because clinical trials are optional, applicants may propose non-intervention studies as long as they align with the FOA focus on intersectional stigma and HIV prevention continuum outcomes.
What is the award ceiling listed for this opportunity?
The award ceiling listed in the provided information is $499,999.
What is the original closing date for the FOA?
The original closing date in the provided information is 2019-01-23.
When was the FOA record created?
The FOA record creation date shown in the provided information is 2018-11-23.
What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.242 and 93.307.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses.
Are community-based and faith-based organizations eligible?
Yes. The FOA highlights faith-based or community-based organizations among additional eligible applicant groups.
Are minority-serving institutions specifically encouraged or eligible?
The FOA highlights multiple institution types, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISISs).
Can federal agencies apply?
Yes. The FOA notes eligible federal agencies among additional eligible applicant groups.
Are U.S. territories and regional organizations eligible?
Yes. The FOA includes U.S. territories or possessions and regional organizations in the highlighted eligible applicant groups.
Are non-U.S. (foreign) organizations eligible?
Yes. The FOA explicitly includes non-U.S. entities (foreign organizations) as eligible applicants.
What kinds of stigma does PRISM expect applicants to consider?
The FOA provides examples of stigmas that may intersect, including stigma related to race/ethnicity, sexual orientation, gender identity, substance use, poverty, immigration status, involvement with the criminal legal system, and sex work. The expectation is to address overlapping stigmas that jointly affect access to HIV testing and prevention services.
Does PRISM emphasize work with populations most affected by HIV and stigma?
Yes. The FOA emphasizes key populations at substantial risk for HIV infection and notes an interest in research that is scientifically rigorous and grounded in communities most affected, including projects led by or conducted in partnership with community organizations and institutions serving disproportionately impacted populations.
What does PRISM mean by connecting stigma reduction to "concrete prevention outcomes"?
The FOA signals that projects should link stigma reduction to measurable HIV prevention continuum outcomes, such as HIV testing uptake and successful connection to ongoing prevention services, rather than focusing only on attitudes or experiences without an outcomes link.
Browse more opportunities from the same category: Health
Next opportunity: Awards for Faculty
Previous opportunity: Diabetes Research Centers (P30)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 19 412
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 19 412) also looked into and applied for these:
| Funding Opportunity |
|---|
| Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 076 Funding Number: PA 19 076 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Development of Rapid Fungal Diagnostics (R21 Clinical Trial Not Allowed) Apply for PA 19 081 Funding Number: PA 19 081 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 19 079 Funding Number: PAR 19 079 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed) Apply for PA 19 082 Funding Number: PA 19 082 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed) Apply for PA 19 083 Funding Number: PA 19 083 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42 Clinical Trial Not Allowed) Apply for PA 19 075 Funding Number: PA 19 075 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed) Apply for PA 19 077 Funding Number: PA 19 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed) Apply for PA 19 080 Funding Number: PA 19 080 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 19 078 Funding Number: PAR 19 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol-HIV/AIDS Program Project (P01 Clinical Trial Optional) Apply for RFA AA 19 002 Funding Number: RFA AA 19 002 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed) Apply for PA 19 094 Funding Number: PA 19 094 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| A Practice-Based Research Network to Transform Mental Health Care: Science, Service Delivery and Sustainability (U19 Clinical Trial Required) Apply for RFA MH 19 225 Funding Number: RFA MH 19 225 Agency: National Institutes of Health Category: Health Funding Amount: $130,000 |
| Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional) Apply for RFA AI 18 058 Funding Number: RFA AI 18 058 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Exploring Molecular Links Between Dietary Interventions and Circadian Rhythm (R01 Clinical Trial Not Allowed) Apply for RFA AG 19 029 Funding Number: RFA AG 19 029 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-infection (R01 Clinical Trial Not Allowed) Apply for PAS 19 097 Funding Number: PAS 19 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed) Apply for PA 19 095 Funding Number: PA 19 095 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed) Apply for PA 19 096 Funding Number: PA 19 096 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: Biofabricated 3D Tissue Models of Nociception, Opioid Use Disorder and Overdose for Drug Screening (UH2/UH3 Clinical Trial Not Allowed) Apply for RFA TR 19 005 Funding Number: RFA TR 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Heal Initiative: Pragmatic Randomized Controlled Trial of Acupuncture for Management of Chronic Low Back Pain in Older Adults (UG3/UH3 Clinical Trial Required) Apply for RFA AT 19 005 Funding Number: RFA AT 19 005 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| HEAL Initiative: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Anatomical and Functional Mapping of Pain-Related Visceral Organ Neural Circuitry (U01 Clinical Trial Optional) Apply for RFA RM 19 001 Funding Number: RFA RM 19 001 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 19 412", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.